Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.
作者信息
Brandão Mariana, Reyal Fabien, Hamy Anne-Sophie, Piccart-Gebhart Martine
机构信息
Université Libre de Bruxelles, Institut Jules Bordet, Bruxelles, Belgium.
Residual Tumor & Response to Treatment Laboratory, PSL Research University, Paris, France.
出版信息
ESMO Open. 2019 May 21;4(3):e000515. doi: 10.1136/esmoopen-2019-000515. eCollection 2019.
Abstract
摘要
相似文献
1
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.
ESMO Open. 2019 May 21;4(3):e000515. doi: 10.1136/esmoopen-2019-000515. eCollection 2019.
2
Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Breast Cancer. 2016 Sep;23(5):789-96. doi: 10.1007/s12282-015-0642-7. Epub 2015 Oct 5.
3
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
4
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.
5
Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment.
Oncotarget. 2018 Sep 14;9(72):33719-33733. doi: 10.18632/oncotarget.26120.
6
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.
7
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.
8
[Not Available].
Bull Cancer. 2016 Jun;103(6 Suppl 1):S76-89. doi: 10.1016/S0007-4551(16)30149-7.
9
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Trials. 2017 Oct 25;18(1):497. doi: 10.1186/s13063-017-2228-5.
10
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Ann Oncol. 2016 Mar;27(3):480-7. doi: 10.1093/annonc/mdv611. Epub 2015 Dec 23.
引用本文的文献
1
Triple-Negative, HER2/Neu, and Ki67 Markers in Breast Cancer Patients Undergoing Standard of Care Treatment in India: Real-World Evidence on Tumor Aggressiveness and Survival Outcomes.
Cureus. 2025 Feb 9;17(2):e78798. doi: 10.7759/cureus.78798. eCollection 2025 Feb.
2
HER2-low status improves prognosis prediction in breast cancer patients receiving neoadjuvant treatment: A comparison of pathological stage, modified CPS+EG scoring system, and Neo-Bioscore.
Chin J Cancer Res. 2024 Dec 30;36(6):729-741. doi: 10.21147/j.issn.1000-9604.2024.06.10.
3
Interactive exploration of a global clinical network from a large breast cancer cohort.
NPJ Digit Med. 2022 Aug 10;5(1):113. doi: 10.1038/s41746-022-00647-0.
4
Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
BMC Cancer. 2022 May 4;22(1):493. doi: 10.1186/s12885-022-09608-y.
5
Triple-negative breast cancer: current treatment strategies and factors of negative prognosis.
J Med Life. 2022 Feb;15(2):153-161. doi: 10.25122/jml-2021-0108.
6
Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital.
Ecancermedicalscience. 2021 Feb 11;15:1185. doi: 10.3332/ecancer.2021.1185. eCollection 2021.
7
Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.
Front Oncol. 2021 Feb 9;10:588533. doi: 10.3389/fonc.2020.588533. eCollection 2020.
8
-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens.
Cancers (Basel). 2021 Jan 20;13(3):370. doi: 10.3390/cancers13030370.
本文引用的文献
1
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Ann Oncol. 2019 Jun 1;30(6):921-926. doi: 10.1093/annonc/mdz055.
2
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.
3
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
4
Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy.
Crit Rev Oncol Hematol. 2018 Dec;132:51-65. doi: 10.1016/j.critrevonc.2018.09.012. Epub 2018 Sep 25.
5
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
Ann Surg. 2019 Mar;269(3):432-442. doi: 10.1097/SLA.0000000000003075.
6
Neoadjuvant treatment: the future of patients with breast cancer.
ESMO Open. 2018 May 17;3(4):e000371. doi: 10.1136/esmoopen-2018-000371. eCollection 2018.
7
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.
8
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Lancet Oncol. 2018 Jan;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5. Epub 2017 Dec 11.
9
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.
Oncotarget. 2017 Sep 23;8(49):86423-86434. doi: 10.18632/oncotarget.21198. eCollection 2017 Oct 17.
10
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.
Zotero 插件